John M. Evans, CEO at Beam Therapeutics Inc. (BEAM), sold 60,000 shares at $25.33 ($1.5M) on 2024-01-31, disclosed to the SEC on 2024-02-02.
Scheduled sale ($1.5M) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| BEAM | SELL | 2026-04-01 | $1.1M | — | Filing → |
| BEAM | SELL | 2026-02-02 | $2.8M | — | Filing → |
| BEAM | SELL | 2025-10-03 | $1.2M | — | Filing → |